Skip to content
2000
Volume 10, Issue 4
  • ISSN: 1570-1786
  • E-ISSN: 1875-6255

Abstract

The re-emergence, in the recent years, of cyclooxygenase as a biological target in therapeutic areas other than inflammation is likely to require new optimized leads, particularly suited for the requirements of specific drug development programs. We developed a convenient synthesis of the known imidazole-based selective COX-2 inhibitors bearing primary sulphonamide and methyl sulfone substituents, via Pd-catalyzed imidazoline N-arylation as a key step, followed by dehydrogenation.

Loading

Article metrics loading...

/content/journals/loc/10.2174/1570178611310040002
2013-05-01
2025-09-03
Loading full text...

Full text loading...

/content/journals/loc/10.2174/1570178611310040002
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test